EUVIMEDEUVIMED entdecken
Open Access

Nilotinib in combination with sunitinib renders MCL-1 for degradation and activates autophagy that overcomes sunitinib resistance in renal cell carcinoma

Tingyu Liu, Xin Yue, Xue Chen, Ru Yan, Chong Wu, Yunzhi Li, Xianzhang Bu, Hui Han, Ran-Yi Liu

Cellular Oncology · 2024-08 · 47 (4) · 1277-1294

DOI: 10.1007/s13402-024-00927-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, online erschienen am 23.02.2024. Verfasst von Tingyu Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Sunitinib, Carcinoma, Renal Cell, Autophagy, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, The Enterprise United Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SunitinibCarcinoma, Renal CellAutophagyDrug Resistance, NeoplasmKidney NeoplasmsPyrimidinesMyeloid Cell Leukemia Sequence 1 ProteinHumansCell Line, TumorAnimalsMice, NudeCell ProliferationDrug SynergismApoptosisXenograft Model Antitumor AssaysMiceMice, Inbred BALB CProteolysisBeclin-1

Stichwörter der Autor:innen

AutophagyCombination therapyMCL-1NilotinibRenal cell carcinomaSunitinib

Substanzen

SunitinibnilotinibPyrimidinesMyeloid Cell Leukemia Sequence 1 ProteinMCL1 protein, humanBeclin-1

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
  • Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, China. yuex5@mail.sysu.edu.cn.
  • School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. hanhui@sysucc.org.cn.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. liury@sysucc.org.cn.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province
  • The Enterprise United Foundation of Guangdong Province

Zitieren

APA

Liu, T., Yue, X., Chen, X., Yan, R., Wu, C., Li, Y., Bu, X., Han, H., & Liu, R. Y. (2024). Nilotinib in combination with sunitinib renders MCL-1 for degradation and activates autophagy that overcomes sunitinib resistance in renal cell carcinoma. Cellular Oncology, 47(4), 1277-1294. https://doi.org/10.1007/s13402-024-00927-9

Vancouver

Liu T, Yue X, Chen X, Yan R, Wu C, Li Y, et al. Nilotinib in combination with sunitinib renders MCL-1 for degradation and activates autophagy that overcomes sunitinib resistance in renal cell carcinoma. Cellular Oncology. 2024;47(4):1277-1294. doi:10.1007/s13402-024-00927-9

BibTeX
@article{Liu2024,
  author = {Liu, Tingyu and Yue, Xin and Chen, Xue and Yan, Ru and Wu, Chong and Li, Yunzhi and Bu, Xianzhang and Han, Hui and Liu, Ran-Yi},
  title = {Nilotinib in combination with sunitinib renders MCL-1 for degradation and activates autophagy that overcomes sunitinib resistance in renal cell carcinoma},
  journal = {Cellular Oncology},
  year = {2024},
  volume = {47},
  number = {4},
  pages = {1277--1294},
  doi = {10.1007/s13402-024-00927-9}
}
Kostenlos starten →